Search research articles
Contact Us
Filters
Showing results (51-60 of 169) with videos related to
Page
of 17
Sort By:
Cancer
|
October 1, 2008
A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience
Atreya Dash, Joseph A Pettus, Harry W Herr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 11, 2011
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy
Matthew D Galsky, Noah M Hahn, Jonathan Rosenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 3, 2010
TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis
Darren R Feldman, Joel Sheinfeld, Dean F Bajorin, et al.
Cancer
|
August 12, 2009
Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma
David J Gallagher, Matthew I Milowsky, Alexia Iasonos, et al.
Journal of Oncology Practice
|
January 21, 2014
Access to chemotherapy services by availability of local and visiting oncologists
Marcia M Ward, Fred Ullrich, Kevin Matthews, et al.
Journal of Oncology Practice
|
January 21, 2014
Projected supply of and demand for oncologists and radiation oncologists through 2025: an aging, better-insured population will result in shortage
Wenya Yang, James H Williams, Paul F Hogan, et al.
Clinical Genitourinary Cancer
|
February 13, 2021
Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic
Michal Sarfaty, Darren R Feldman, Michael J Morris, et al.
Plos One
|
January 1, 2019
A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor
Mark D M Leiserson, Vasilis Syrgkanis, Amy Gilson, et al.
Japanese Journal of Clinical Oncology
|
October 27, 2022
Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial
Yoshihiko Tomita, Ko Kobayashi, Go Kimura, et al.
European Urology Oncology
|
March 15, 2022
Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial
Johannes Alfred Witjes, Matthew D Galsky, Jürgen E Gschwend, et al.
Page
of 17
Search research articles
Search
Showing results (51-60 of 169) with videos related to
Sort By:
Page
of 17
Cancer
|
October 1, 2008
A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience
Atreya Dash, Joseph A Pettus, Harry W Herr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 11, 2011
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy
Matthew D Galsky, Noah M Hahn, Jonathan Rosenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 3, 2010
TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis
Darren R Feldman, Joel Sheinfeld, Dean F Bajorin, et al.
Cancer
|
August 12, 2009
Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma
David J Gallagher, Matthew I Milowsky, Alexia Iasonos, et al.
Journal of Oncology Practice
|
January 21, 2014
Access to chemotherapy services by availability of local and visiting oncologists
Marcia M Ward, Fred Ullrich, Kevin Matthews, et al.
Journal of Oncology Practice
|
January 21, 2014
Projected supply of and demand for oncologists and radiation oncologists through 2025: an aging, better-insured population will result in shortage
Wenya Yang, James H Williams, Paul F Hogan, et al.
Clinical Genitourinary Cancer
|
February 13, 2021
Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic
Michal Sarfaty, Darren R Feldman, Michael J Morris, et al.
Plos One
|
January 1, 2019
A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor
Mark D M Leiserson, Vasilis Syrgkanis, Amy Gilson, et al.
Japanese Journal of Clinical Oncology
|
October 27, 2022
Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial
Yoshihiko Tomita, Ko Kobayashi, Go Kimura, et al.
European Urology Oncology
|
March 15, 2022
Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial
Johannes Alfred Witjes, Matthew D Galsky, Jürgen E Gschwend, et al.
Page
of 17